These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38247730)

  • 1. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
    Szigeti B; Weiss B; Rosas FE; Erritzoe D; Nutt D; Carhart-Harris R
    Psychol Med; 2024 Jun; 54(8):1717-1724. PubMed ID: 38247730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
    Erritzoe D; Barba T; Spriggs MJ; Rosas FE; Nutt DJ; Carhart-Harris R
    J Psychopharmacol; 2024 May; 38(5):458-470. PubMed ID: 38520045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.
    Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Psychol Med; 2024 Jan; 54(1):178-192. PubMed ID: 37264814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
    Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS
    BMJ; 2024 Aug; 386():e078607. PubMed ID: 39168500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.
    Nayak SM; Bari BA; Yaden DB; Spriggs MJ; Rosas FE; Peill JM; Giribaldi B; Erritzoe D; Nutt DJ; Carhart-Harris R
    Psychedelic Med (New Rochelle); 2023 Mar; 1(1):18-26. PubMed ID: 37337526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM.
    Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Psychol Med; 2024 Jan; 54(1):217. PubMed ID: 37466289
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 11. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.
    Poulin JM; Bigford GE; Lanctôt KL; Giacobbe P; Schaffer A; Sinyor M; Rabin JS; Masellis M; Singnurkar A; Pople CB; Lipsman N; Husain MI; Rosenblat JD; Cao X; MacIntosh BJ; Nestor SM
    Trials; 2024 Jul; 25(1):441. PubMed ID: 38956594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.
    Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J
    Curr Psychiatry Rep; 2022 Oct; 24(10):573-581. PubMed ID: 35953638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.
    Copa D; Erritzoe D; Giribaldi B; Nutt D; Carhart-Harris R; Tagliazucchi E
    J Affect Disord; 2024 May; 353():60-69. PubMed ID: 38423367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Psilocybin compared with escitalopram for depression].
    Strous JFM
    Ned Tijdschr Geneeskd; 2022 Jan; 166():. PubMed ID: 35138714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
    Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.
    Mischoulon D; Price LH; Carpenter LL; Tyrka AR; Papakostas GI; Baer L; Dording CM; Clain AJ; Durham K; Walker R; Ludington E; Fava M
    J Clin Psychiatry; 2014 Apr; 75(4):370-6. PubMed ID: 24500245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.